AIP
GTBP icon

Ameritas Investment Partners’s GT Biopharma GTBP Stock Holding History

Ameritas Investment Partners’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-62
Closed -$5K – 3134
2022
Q1 		$5K Hold
62
– – ﹤0.01% 2965
2021
Q4 		$6K Hold
62
– – ﹤0.01% 3014
2021
Q3 		$13K Hold
62
– – ﹤0.01% 2873
2021
Q2 		$29K Buy
+62
New +$25.8K ﹤0.01% 2522

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's GTBP Position: Q2 2022 in Review

Ameritas Investment Partners sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 62 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in GTBP in Q2 2021 and held it in 4 quarters. The position peaked at $29K in Q2 2021. 47 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

  • Ameritas Investment Partners reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 62 GT Biopharma shares in Q2 2022, an estimated $5K.
  • Ameritas Investment Partners first reported a position in GT Biopharma in Q2 2021 and held it in 4 quarters.
  • Ameritas Investment Partners's GT Biopharma position peaked at $29K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.